Azenta, Inc. Re-Affirms Revenue Guidance for the Second Fiscal Quarter of 2022 Which Ended on March 31, 2022
April 28, 2022 at 04:06 pm EDT
Share
Azenta, Inc. re-affirmed revenue guidance for the second fiscal quarter of 2022 which ended on March 31, 2022. The company expects second quarter revenue to be within the previously issued guidance range.
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
AZENTA, INC. 
